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Background. Schizophrenia is a heterogeneous disorder in terms of patient response to antipsychotic treatment.
Understanding the heterogeneity of treatment response may help to guide treatment decisions. This study was
undertaken to capture inherent patterns of response to antipsychotic treatment in patients with schizophrenia,
characterize the subgroups of patients with similar courses of response, and examine illness characteristics at baseline
as possible predictors of response.
Method. Growth mixture modeling (GMM) was applied to data from a randomized, double-blind, 12-week study of
628 patients with schizophrenia or schizo-aﬀective disorder treated with risperidone or olanzapine.
Results. Four distinct response trajectories based on Positive and Negative Syndrome Scale (PANSS) total score over
12 weeks were identiﬁed: Class 1 (420 patients, 80.6%) with moderate average baseline PANSS total score showing
gradual symptom improvement; Class 2 (65 patients, 12.5%) showing rapid symptom improvement; Class 3
(24 patients, 4.6%) with high average baseline PANSS total score showing gradual symptom improvement; and Class
4 (12 patients, 2.3%) showing unsustained symptom improvement. Latent class membership of early responders (ER)
and early non-responders (ENR) was determined based on 20% symptom improvement criteria at 2 weeks and
ultimate responders (UR) and ultimate non-responders (UNR) based on 40% symptom improvement criteria at
12 weeks. Baseline factors with potential inﬂuence on latent class membership were identiﬁed.
Conclusions. This study identiﬁed four distinct treatment response patterns with predominant representation of
responders or non-responders to treatment in these classes. This heterogeneity may represent discrete endopheno-
types of response to treatment with diﬀerent etiologic underpinnings.
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Introduction
Schizophrenia is a heterogeneous disorder in terms of
response to antipsychotic treatment. Several studies
have found that about 70% of patients fail to experi-
ence at least minimal response early in treatment
(Kinon et al. 1993, 2008; Ascher-Svanum et al. 2008).
Currently available medications for schizophrenia
are eﬀective for only about 50% of patients (Kerwin
& Osborne, 2000; Lieberman et al. 2005; Miyamoto
et al. 2005). Poor symptom response is associated
with premature treatment discontinuation, symptom
exacerbations, relapse, and increased risk of hospi-
talization with resultant higher costs of treatment
(Ayuso-Gutierrez & del Rio Vega, 1997; Perkins, 2002;
Thieda et al. 2003; Liu-Seifert et al. 2005). There is,
therefore, a need to better understand the character-
istics of the group of patients who are non-responsive
to treatment and to ﬁnd better treatment options for
them.
There may be two important areas to observe pre-
dictors of response: (1) disease state at baseline before
initiation of treatment; and (2) early symptom changes
after commencement of treatment. Cognitive func-
tioning deﬁcits (Harvey et al. 2005), poor pre-morbid
functioning (Rabinowitz et al. 2006), earlier age of on-
set (Meltzer et al. 1997), duration of untreated psy-
chosis (Ucok et al. 2004; Perkins, 2005) and male
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ORIGINAL ARTICLEgender (Aleman et al. 2003) are baseline factors that
have been found to be associated with poor treatment
response. Patients likely to remain as non-responders
to treatment based on their early non-response to
treatment at weeks 1 or 2 have been reported. Correll
et al. (2003) observed that early non-response to treat-
ment, as measured by a 20% reduction in Brief
Psychiatric Rating Scale (BPRS) total score at week 1,
predicted non-response at 4 weeks for 100% of
patients. Other studies have suggested the hypothesis
that early non-response to treatment within the ﬁrst
2 weeks of treatment initiation is a good indicator of
treatment refractoriness (Correll et al. 2003; Leucht
et al. 2007; Kinon et al. 2008).
Estimates of response from early symptom changes
have used a priori cut-oﬀ scores (percentage improve-
ment) to deﬁne treatment response and do not ac-
count for inter-individual variation in drug response.
Furthermore, the focus has been on early response at
a particular time point, which could be 1 or 2 weeks,
depending on the study. Embedded trajectories in
antipsychotic treatment response without a priori cut-
oﬀs for improvement in symptoms or a time point for
early response may be able to bring new insight into
treatment response patterns to antipsychotic drugs.
Growth mixture modeling (GMM) has been explored
as an alternative method to classify clinical pro-
gression patterns. This is a technique that identiﬁes
homogeneous trajectories from varying individual re-
sponses. Recent applications of GMM in medical re-
search include trajectories of change in depression
severity during treatment with antidepressants (Uher
et al. 2010) and examination of placebo response
in antidepressant trials (Muthe ´n & Brown, 2009). The
objectives of this analysis were to: (1) capture inherent
patterns of response to risperidone or olanzapine
treatment in patients with schizophrenia; (2) charac-
terize the subgroups of patients with similar courses of
treatment response; and (3) examine various illness
characteristics at baseline before initiation of treatment
as possible predictors of response.
Method
Study design
Data for this study were obtained from a randomized,
double-blind, parallel, 12-week study (Kinon et al.
2010) consisting of 628 patients (aged 18–65 years)
meeting the diagnostic criteria for schizophrenia,
schizo-aﬀective disorder or schizophreniform disorder
according to DSM-IV. The trial was conducted in ac-
cordance with the Declaration of Helsinki and all ap-
plicable regulatory requirements. This study was
conducted at 64 study centers in three countries from
May 2006 to December 2007. Eligible patients pro-
vided written informed consent before undergoing
any study procedure or receiving any study treatment.
Details of the study design consisting of three study
periods and inclusion/exclusion criteria can be found
in the primary manuscript of this clinical trial (Kinon
et al. 2010). Study period I consisted of screening of
patients. Study period II consisted of patients receiv-
ing 2 weeks of open-label treatment with risperidone
2 to 6 mg/day and, at the end of 2 weeks, patients
were classiﬁed as early responders (ER) or early non-
responders (ENR) based on a-priori criteria of 20%
improvement in Positive and Negative Syndrome
Scale (PANSS; Kay et al. 1987) total scores. Details re-
garding the 20% improvement criteria for the PANSS
scores are given in the primary manuscript (Kinon
et al. 2010). After early study discontinuation, 83% of
patients (522/628) entered study period III double-
blinded (post-baseline data were not available for one
patient). Early responders (o20% improvement in
PANSS total score at week 2) to risperidone treatment
continued the same treatment for another 10 weeks.
Early non-responders (<20% improvement in PANSS
total score at week 2) to risperidone treatment were
randomly assigned in a 1:1 ratio to either risperidone
2–6 mg/dayorolanzapine10to20 mg/dayforanother
10 weeks of treatment (see Supplementary Fig. 1.
available online).
For the current analysis, the hypothesis is that
longitudinal response proﬁles may exist that can
better characterize response to treatment compared
to cross-sectional dichotomization of response/non-
response based on a-priori degree of categorical
symptom improvement after a speciﬁed duration
of treatment. Therefore, the analysis was conducted
using pooled treatment groups of risperidone and
olanzapine.
Statistical analysis
To investigate the heterogeneity in treatment re-
sponse, we applied GMM. GMM is a combination
of growth models to examine the development of
individuals on an outcome variable (PANSS total,
PANSS positive, and PANSS negative scores) over
time and a mixture model to identify subpopulations,
referred to as response patterns/trajectories in this
paper, using categorical latent variables. Growth
modeling uses random coeﬃcients, termed growth
factors, to allow for individual diﬀerences in devel-
opment within response trajectories. GMM uses out-
come at all time points, allows for missingness of data
under a missing at random assumption, and allows
estimation of the probability of an individual’s mem-
bership to the identiﬁed trajectories. GMM was ﬁt into
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program (Muthe ´n & Muthe ´n, 2007). The parameters of
this model are estimated in the maximum-likelihood
framework using an expectation–maximization (EM)
algorithm. A broad overview of GMM can be found in
the Handbook of Quantitative Methodology for the Social
Sciences (Muthe ´n, 2004).
GMM was applied to PANSS total, PANSS positive,
and PANSS negative scores at eight time points (visits)
over 12 weeks of study. A piece-wise GMM model was
used to model trajectories. Baseline and the ﬁrst three
post-baseline visits until week 3 were modeled quad-
ratically (linear and quadratic growth factor) and
the remaining four visits over 9 weeks were modeled
linearly (linear growth factors). Conceptually, an
individual’s PANSS total score and subscores can be
understood by identifying the trajectory they belong to
and then applying the trajectory-speciﬁc growth fac-
tors. Throughout this paper, estimated mean growth
factors are presented. To identify the appropriate
number of response trajectories, the Bayesian Infor-
mation Criterion (BIC) was used. To test for diﬀer-
ences between identiﬁed trajectories (classes), analysis
of variance (ANOVA) was used for continuous vari-
ables and Fisher’s exact test was used for categorical
variables, with class as the independent variable.
Measures
The distribution of ER, ENR, ultimate responders (UR:
o40% improvement in PANSS total score at end-
point) and ultimate non-responders (UNR: <40%
improvement in PANSS total score at endpoint)
in the identiﬁed latent classes was determined.
Secondary eﬃcacy measures studied included the
Montgomery–Asberg Depression Rating Scale
(MADRS; Montgomery & Asberg, 1979), the Clinical
Global Impression (CGI) Severity and Improvement
scale (Guy, 1976), and the Brief Assessment of
Cognition in Schizophrenia (BACS; Keefe et al. 2004).
Quality of life measures included the Heinrich
Carpenter Quality of Life Scale (QLS; Heinrichs et al.
1984), the Subjective Well-being Under Neuroleptics
(SWN) scale (Naber et al. 2001) the and Schizophrenia
Objective Functioning Instrument (SOFI; Kleinman
et al. 2009). Extrapyramidal symptoms (EPS) were
measured by the Abnormal Involuntary Movement
Scale (AIMS; Guy, 1976), the Barnes Akathisia Scale
(BAS; Barnes, 1989) and the Modiﬁed Simpson–Angus
Rating Scale (SA; Simpson & Angus, 1970).
Results
GMM analysis of PANSS total scores for all patients
treated with risperidone or olanzapine over 12 weeks
revealed four distinct response patterns as shown in
Fig. 1 and described below. The four-class model was
selected from ﬁve diﬀerent sequential piece-wise
models using BIC, with a smaller BIC indicating a
better model (see Supplementary Table 1, available
online).
Class 1: Gradual symptom improvement and
moderate average baseline PANSS score
(420 patients, 80.6%)
The average baseline PANSS total score for patients
in this class was 88.7 points with a subsequent average
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Class 3, 4.6%, 24 patients, ENR = 23, ER = 1
Class 4, 2.3%, 12 patients, ENR = 9, ER = 3
Class 1, 80.6%, 420 patients, ENR = 337, ER = 83
Class 2, 12.5%, 65 patients, ENR = 0, ER = 65
Fig. 1. Growth mixture modeling (GMM) analysis of the Positive and Negative Syndrome Scale (PANSS) total score reveals
four distinct latent classes of treatment response. ER, early responders (o20% improvement in PANSS total at week 2);
ENR, early non-responders.
The heterogeneity of antipsychotic response 1293improvement of 22.5 points after 12 weeks of treat-
ment. Patients in this class were a mixture of re-
sponders and non-responders to treatment with mostly
non-responders, consisting of 80% ENR and 87%
UNR patients; o89% of ENR patients continued to
UNR status.
The responding patients in this class may be charac-
terized as gradual responders to treatment, with re-
sponse distributed throughout the 12-week treatment
period. Fifty-ﬁve patients in this class reached ulti-
mate response (13.1%) and constituted 10.6% of the
total patients.
Class 2: Rapid symptom improvement
(65 patients, 12.5%)
The average baseline PANSS total score for patients in
this class was 100.1 followed by a subsequent average
improvement of 50.9 points after 12 weeks of treat-
ment. Class 2 was uniquely distributed with 100% ER
patients; 66% progressed to UR after 12 weeks of
treatment.
Patients in this class were distinctly rapid re-
sponders to treatment, with rapid initial response for
the ﬁrst 2 weeks, followed by a more gradual response
for the next 10 weeks. Forty-three patients in this class
reached ultimate response (66%) and constituted 8.3%
of the total patients.
Class 3: Gradual symptom improvement and high
average baseline PANSS score (24 patients, 4.6%)
The average baseline PANSS total score for patients in
this class was 123.7 points with a subsequent average
improvement of 28.0 points after 12 weeks of treat-
ment. The trajectory shape of this class was similar
to Class 1, but with a higher average PANSS total
score at baseline compared to Class 1. Class 3 was
uniquely distributed with 96% ENR and 96% UNR
patients; o96% ENR patients continued to UNR
status.
Class 4: Unsustained symptom improvement
(12 patients, 2.3%)
The average baseline PANSS total score for patients in
this class was 95.1, showing initial average symptom
improvement of 27.9 points followed by worsening of
symptoms. Class 4 was represented by 75% ENR and
100% UNR patients; all of the ENR patients continued
to UNR status.
The observed trajectories of individuals classiﬁed
into the four latent classes are shown in Fig. 2. The
patient demographics for the four latent classes are
shown in Table 1. The four classes were signiﬁcantly
diﬀerent in age at onset, ethnicity, EPS, PANSS total,
CGI severity, MADRS, QLS total, SOFI global, and
Class 3: gradual response - high PANSS total Class 4: unsustained response 
Class 1: gradual response - moderate PANSS total Class 2: rapid response 
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Fig. 2. The observed trajectories of individuals classiﬁed into the four latent classes are shown as broken lines and the
solid line represents the model-estimated means shown in Fig. 1. PANSS, Positive and Negative Syndrome Scale.
1294 M. Case et al.SWN total scores and were primarily driven by dif-
ferences between group 3 and the remaining groups.
Because Class 1 was a combination of UR and UNR
patients, these subgroups were separated and the
baseline demographics compared in Table 2; the major
diﬀerences were a lower number of previous illness
episodes and a higher age at onset for UR patients
compared to UNR patients.
Baseline demographics of UNR patients from Class
1 are compared with UNR patients from Class 3 in
Table 2. UNR patients in these two classes were sig-
niﬁcantly diﬀerent in age at onset, ethnicity, EPS,
PANSS total, CGI severity, MADRS, QLS total, SOFI
global, and SWN total scores Baseline demographics
of gradual responders (UR from Class 1) are compared
with rapid responders (UR from Class 2) in Table 2.
Gradual and rapid responders were signiﬁcantly dif-
ferent in PANSS total, CGI severity, and SWN total
scores. However, the p values in Tables 1 and 2 should
be interpreted as hypothesis generating as opposed to
hypothesis conﬁrming.
GMM analysis of PANSS negative scores also re-
vealed four classes similar to the PANSS total analysis.
Analysis of PANSS positive scores did not indicate
Class 4 (unsustained response) as observed in the
PANSS total and PANSS negative analysis. Class
membership of ER/ENR and UR/UNR patients in the
PANSS negative and PANSS positive scores analysis
was similar to the PANSS total scores analysis (data
not included).
Comparison of PANSS total score GMM analysis
of the total patient group versus the early
non-responder group
PANSS total score GMM analysis of 370 ENR patients
was compared with the GMM analysis of the total
Table 1. Demographics at baseline for patients in the four latent classes of PANSS total score GMM analysis
Class 1
(420 patients)
Class 2
(65 patients)
Class 3
(24 patients)
Class 4
(12 patients) p value
Gender, male 62 55 75 50 0.302
Age, years 42.1¡11.0 40.7¡10.4 38.9¡12.4 45.0¡13.3 0.307
Age at onset, years 25.3¡9.9 26.4¡9.9 20.4¡6.4 30.3¡11.2 0.020
Ethnicity/race 0.039
Caucasian 42.8 52.3 50 66.7
African descent 47.9 36.9 25 16.7
Hispanic 8.1 9.2 20.8 16.7
Other 1.2 1.5 4.2 –
Diagnosis 0.982
Schizophrenia 75.2 73.8 79.2 75
Schizo-aﬀective disorder 19.0 18.5 20.8 16.7
Schizophreniform 5.7 7.7 – 8.3
Duration of current episode, days 27¡80 20¡42 30¡96 21¡37 0.899
Number of previous episodes 5¡26 3¡37 ¡21 4¡5 0.853
Extrapyramidal symptoms
AIMS 0.7¡2.2 0.7¡1.9 4.7¡5.5 1.7¡5.2 <0.001
BAS total score 0.5¡1.6 0.6¡1.5 2.2¡2.7 0.2¡0.4 <0.001
SA total score 0.9¡2.2 1.2¡2.9 4.9¡5.9 1.5¡4.3 <0.001
BACS score 41.0¡22.0 36.8¡18.9 37.7¡31.4 41.3¡35.0 0.514
PANSS total score 88.6¡10.6 100.7¡11.2 125.1¡9.1 94.6¡14.9 <0.001
CGI severity score 4.5¡0.6 5.0¡0.5 5.0¡0.7 4.8¡0.6 <0.001
CGI improvement score 4.1¡0.5 4.2¡0.6 4.0¡0.6 4.1¡0.7 0.206
MADRS total score 15.5¡8.8 17.5¡9.1 23.3¡8.0 23.9¡10.2 <0.001
Quality of Life Scale total score 52.8¡21.0 48.3¡20.8 32.6¡15.8 47.6¡21.5 <0.001
SOFI global score 57.8¡16.8 52.3¡15.3 40.1¡12.2 49.0¡15.2 <0.001
SWN total score 78.2¡16.8 70.0¡16.3 71.1¡18.0 72.3¡14.0 <0.001
Body mass index, kg/m
2 30.6¡8.2 30.9¡9.4 27.9¡5.7 28.2¡8.9 0.306
AIMS, Abnormal Involuntary Movement Scale; BACS, Brief Assessment of Cognition in Schizophrenia; BAS, Barnes
Akathisia Scale; CGI, Clinical Global Impression; GMM, growth mixture modeling; MADRS, Montgomery–Asberg
Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; SA, Modiﬁed Simpson–Angus Scale; SOFI,
Schizophrenia Objective Functioning Instrument; SWN, Subjective Well-being under Neuroleptics.
Values given as percentage or mean ¡ standard deviation.
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distributions of patients were observed. Classes 1, 2
and 3 in the ENR group consisted of 22, 8 and 339
patients respectively, and the all-patient group con-
sisted of 23, 9 and 337 patients respectively.
Discussion
The GMM analysis of symptom progression and re-
sponse among patients with schizophrenia treated
with risperidone or olanzapine for 12 weeks revealed
heterogeneity in treatment response to antipsychotic
treatment. The analysis provided an insight into
the complexity of antipsychotic response across
individuals and identiﬁed four distinct trajectories
(classes) of response. The majority of patients were
distributed in a class characterized by gradual im-
provement in illness symptoms (Class 1: 80.6%, 365/
420 patients were UNR). The next major trajectory was
characterized by rapid improvement in symptoms for
the ﬁrst 2 weeks, followed by a more gradual im-
provement over the next 10 weeks of treatment (Class
2: 12.5%, 43/65 patients were UR). Classes 3 and 4
were smaller, with Class 3 (4.6%) having the highest
baseline PANSS total score and gradual symptom
improvement, and Class 4 (2.3%) characterized by an
unsustained improvement in illness symptoms; both
Classes 3 and 4 consisted of o96% UNR patients.
Table 2. Comparison of baseline patient demographics for UNR in Class 3, UNR in Class 1, UR in Class 1 (gradual responders), and
UR in Class 2 (rapid responders) from the PANSS total score analysis
UNR Class 3
(n=23)
UNR Class 1
(n=365) p value
Gradual
responders
UR Class 1
(n=55)
Rapid
responders
UR Class 2
(n=43) p value
Gender, male 73.9 62.7 0.373 58.2 62.8 0.682
Age, years 39.2¡12.7 42.2¡11.0 0.199 41.4¡11.3 39.8¡11.2 0.484
Age at onset, years 20.4¡6.6 24.8¡9.6 0.031 28.4¡11.4 25.2¡8.8 0.135
Ethnicity/race 0.021 0.517
Caucasian 47.8 43.0 41.8 55.8
African descent 26.1 48.5 43.6 30.2
Hispanic 21.7 7.4 12.7 11.6
Other 4.3 1.1 1.8 2.3
Diagnosis 1.000 0.627
Schizophrenia 78.3 74.5 80.0 74.4
Schizo-aﬀective 21.7 19.7 14.5 18.6
Schizophreniform – 5.8 5.5 7.0
Duration of current episode, days 30¡96 27¡85 0.868 25¡40 22¡50 0.754
Number of previous episodes 7¡21 6¡27 0.802 3¡23 ¡4 0.553
Extrapyramidal symptoms
AIMS 4.9¡5.6 0.6¡1.9 <0.001 1.6¡3.4 0.5¡1.6 0.058
BAS total score 2.3¡2.7 0.5¡1.5 <0.001 0.8¡1.9 0.3¡1.0 0.055
SA total score 5.1¡6.0 0.8¡2.0 <0.001 1.7¡3.4 1.0¡2.8 0.330
BACS score 37.6¡32.1 41.3¡21.5 0.431 38.9¡25.2 34.7¡16.6 0.349
PANSS total scores 125.2¡9.3 88.0¡10.6 <0.001 92.5¡10.0 103.0¡10.9 <0.001
CGI improvement score 4.0¡0.5 4.1¡0.5 0.387 4.2¡0.6 4.2¡0.4 0.863
CGI severity score 5.0¡0.7 4.5¡0.6 <0.001 4.8¡0.6 5.1¡0.3 0.004
MADRS total score 23.5¡8.1 15.7¡8.8 <0.001 14.1¡8.7 17.6¡8.3 0.051
Quality of Life Scale total score 33.3¡15.7 52.7¡20.7 <0.001 53.6¡23.6 45.0¡19.3 0.058
SOFI global score 40.3¡12.5 58.1¡16.7 <0.001 55.7¡18.0 49.3¡15.0 0.067
SWN total score 70.7¡18.3 78.2¡16.5 0.044 78.5¡18.6 67.3¡13.9 0.002
Body mass index, kg/m
2 27.5¡5.4 30.6¡8.2 0.072 30.7¡7.8 28.8¡7.7 0.218
AIMS, Abnormal Involuntary Movement Scale; BACS, Brief Assessment of Cognition in Schizophrenia; BAS, Barnes
Akathisia Scale; CGI, Clinical Global Impression; GMM, growth mixture modeling; MADRS, Montgomery–Asberg
Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; SA, Modiﬁed Simpson–Angus Scale; SOFI,
Schizophrenia Objective Functioning Instrument; SWN, Subjective Well-being under Neuroleptics; UR, Ultimate
responder (o40% improvement in PANSS total at 12 weeks); UNR, ultimate non-responder.
Values given as percentage or mean ¡ standard deviation.
1296 M. Case et al.Treatment response characteristics of patients in the
four classes are summarized in Fig. 3.
Responders to treatment in Class 2
Class 2 was uniquely represented by 100% of ER
patients. The subgroup of rapid responders to treat-
ment has been identiﬁed in several studies. Marques
et al. (in press) identiﬁed a subset of rapid responders
in a placebo-controlled study in which 420 patients
with schizophrenia were treated for 6 weeks with
haloperidol or olanzapine. The rapid responders were
exclusively from the drug-treated group and showed
>70% improvement and consisted of 17% of the
drug-treated group. Levine & Rabinowitz (2010) also
identiﬁed a subgroup of rapid responders in their
study of 497 patients with ﬁrst-episode schizophrenia
randomly assigned to risperidone or haloperidol.
The rapid responders showed 59% improvement in
PANSS total score during the ﬁrst 4 weeks of treat-
ment and consisted of 19% of the treatment group.
A subgroup of rapid responders termed as early
persistent responders was identiﬁed in data from
three 6-week, double-blind, placebo-controlled trials
in patients with schizophrenia (Glick et al. 2009).
A rapid decrease in mean PANSS total scores of
40.7 points was observed in 23.5% of patients. Unlike
the results from Marques et al. (in press), rapid re-
sponse was also observed in the placebo-treated group
(14.2%; mean decrease in PANSS total: 37.3 points).
A subgroup of rapid responders was also identiﬁed in
a depression study consisting of 807 patients treated
with escitalopram or nortriptyline for 12 weeks (Uher
et al. 2010). The majority of patients (75%) were
described as gradual responders whereas a smaller
group (25%) displayed rapid response for the ﬁrst
3 weeks followed by a gradual response over the re-
maining treatment period.
Rapid response to treatment in patients with schizo-
phrenia has been associated with baseline excess pro-
duction of dopamine as measured by elevated levels
of the dopamine metabolite homovanillic acid in
plasma (pHVA; Garver et al. 2000). Prior to initiation
of treatment with haloperidol, patients (n=32) were
assessed for pHVA levels. Patients with high pHVA
displayed a >30% reduction in BPRS psychosis score
by day 4 after initiating treatment. A delayed-response
psychosis was shown to be associated with low-to-
normal pHVA. A signiﬁcant relationship has been re-
ported between dopamine D2 receptor (DRD2) genetic
variation and treatment response in patients with ﬁrst-
episode schizophrenia (Lencz et al. 2006).
The rapid responders in this study (Class 2) were
found to be more ill than responders in Class 1, yet
displayed dramatic illness improvement. As it is well
accepted that schizophrenia may have complex gen-
etic underpinnings, the subset of rapid responders
repeatedly observed in schizophrenia studies may
represent a unique endophenotype that is responsive
to antipsychotic treatment. Endophenotypes are
characteristics reﬂecting actions of fewer genes than
the more complex phenotype of schizophrenia. Identi-
fying endophenotypes in schizophrenia may aid in
understanding the disease pathology and in develop-
ing new and eﬀective medications. Additional re-
search focusing on speciﬁc genetic testing may lend
support to this idea.
Rapid and gradual responders to treatment in
Classes 1 and 2
Responders to antipsychotic treatment were dis-
tributed mainly in Classes 1 and 2. Patients in Class 2
were rapid responders whereas those in Class 1 were
gradual responders. The literature has been divided
about early onset and delayed onset of response to
521 patients
Class 1: 420 patients
Gradual response
Moderate PANSS score
Class 2: 65 patients
Rapid response
Class 3: 24 patients
Gradual response
High PANSS score
Class 4: 12 patients
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Fig. 3. Treatment response characteristics of patients in the four classes. ER, early responders (o20% improvement in
PANSS total at week 2); ENR, early non-responders; UR, ultimate responders (o40% improvement in PANSS total at
12 weeks); UNR, ultimate non-responders; PANSS, Positive and Negative Syndrome Scale.
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response to treatment occurs after about 2–3 weeks of
antipsychotic treatment (Agid et al. 2003). The early
onset hypothesis proposes more improvement in the
earlier weeks than in the later weeks of antipsychotic
treatment. It is possible that the delayed onset and
early onset hypotheses reﬂect the gradual and rapid
responders respectively. A similar observation has
been reported in a study consisting of 1128 patients
receiving paliperidone extended-release or placebo for
6 weeks (Glick et al. 2009). An early persistent response
(rapid response) was observed in 23.5% of patients
and a late persistent response (gradual response) in
16.3% of patients in the drug-treated group.
Non-responders to treatment in Classes 3 and 4
Ultimate non-responders to treatment were dis-
tributed in all classes, with the majority being dis-
tributed in Class 1 (70%). UNR patients in Classes 3
and 4 (combined total: 6.7%) were unique in that they
represented a class consisting of almost all (o96%)
UNR patients and were characterized by a greater
severity of depressive symptoms as assessed by the
MADRS. Non-responding patients in Classes 3 and 4
may belong to an endophenotype representing treat-
ment-refractory patients.
Baseline predictors of response to antipsychotic
treatment
The baseline characteristics of UNR patients from
Class 3 (4.4%) were distinctly diﬀerent from UNR
patients from Class 1 (70%). UNR patients from
Class 3 were characterized with high extrapyramidal
(AIMS, BAS and SA) and depression (MADRS)
symptoms, low quality of life measures (SOFI, SWN
and QLS), younger age at onset of illness, Hispanic
ethnicity, and higher CGI severity and PANSS total
scores (all with signiﬁcant p values). Younger age
at onset of illness (Meltzer et al. 1997), high EPS
(Rabinowitz et al. 2006), poor social functioning (Haro
et al. 2008) and depressive symptoms (Moller, 2005)
have been associated with poor treatment response.
These baseline characteristics of Class 3 patients were
also observed in the GMM analysis of PANSS positive
and PANSS negative scores analysis (data not in-
cluded). These results indicate a strikingly worse
clinical and functional proﬁle at baseline for one sub-
group of UNR patients (Class 3). Although the UNR
patients in the two classes (Classes 1 and 3) did not
attain the a-priori criteria for response, how these two
groupsofpatientsmightcomparewithlongerduration
of treatment or with a change in treatment regimen
is worth further study, in addition to understanding
what seems to be a greater preponderance of patients
with a Hispanic origin in patients with the worst
clinical status.
UR patients (gradual responders in Class 1 and
rapid responders in Class 2) were observed to have a
lower number of previous episodes compared to UNR
patients in Classes 1 and 3. A higher number of pre-
vious episodes as a predictor of poor treatment out-
come has been reported in a cluster analysis of 1449
patients with schizophrenia (Lipkovich et al. 2009).
Rapid responders were diﬀerentiated from gradual
responders by a higher psychopathology scores (CGI
severity and PANSS total) and a lower SWN score
(all signiﬁcant p values).
Accuracy of 20% symptom improvement at 2 weeks
to classify early non-responders to treatment
Early non-responders to treatment were distributed in
Classes 1, 3 and 4. The accuracy of the a priori 20%
symptom improvement cut-oﬀ at week 2 to classify
ENR patients is indicated by the high percentage of
ENR patients at week 2 continuing to UNR status at
week 12 in these classes. Comparison of the GMM
analysis of the total patient group versus the 370 ENR
group revealed three overlapping classes. Therefore,
the 20% a-priori improvement cut-oﬀ at 2 weeks to
identify non-responding patients early in the treat-
ment may be a useful and accurate tool. However,
there is a greater risk of misclassifying a responder
to treatment as ENR at 2 weeks in Class 1 (gradual
responder) compared to Classes 3 and 4.
Limitations
The four-class solution to these data is a function of the
sample size and the study population. With larger
sample sizes, it is possible that other classes may
emerge or the current large classes may split into
subclasses. Additional research focusing on speciﬁc
genetic testing may lend support to the rapid re-
sponders and treatment-refractory non-responder
endophenotypes. This analysis consisted of patients in
a clinical trial setting; in the naturalistic patient popu-
lation with polypharmacy, the observed trajectories
may change.
Conclusions
This study identiﬁed four distinct treatment response
patterns in patients with schizophrenia treated with
risperidone or olanzapine. The majority of patients
were distributed in a class characterized by gradual
improvement in illness symptoms (Class 1: 80.6%).
A unique class distributed predominantly with ER
1298 M. Case et al.patients showing a rapid improvement in illness
symptoms for the ﬁrst 2 weeks followed by a more
gradual improvement may represent a subset of
patients responsive to atypical antipsychotic drugs
(Class 2). Among responders to treatment, two types
of response were observed: gradual responders and
rapid responders. Classes 3 and 4 consisting of almost
all UNR patients may represent treatment-refractory
patients. This heterogeneity may represent discrete
endophenotypes of response to treatment with diﬀer-
ent etiologic underpinnings. Current ﬁndings also
show that the a-priori deﬁnition of early non-response
to treatment seems to be an accurate threshold and a
useful tool for predicting longer symptom response
and trajectory class. Baseline PANSS total score, EPS,
depressive symptoms, quality of life measures, and
age at onset may have potential inﬂuence on mem-
bership in the latent classes.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
psm).
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